首页> 外文期刊>The East African medical journal >Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
【24h】

Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.

机译:非洲人口女性乳腺癌中雌激素和孕激素受体,Ki-67,p53和BCL-2蛋白,组织蛋白酶D,尿激酶纤溶酶原激活物和尿激酶纤溶酶原激活物受体的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine the expression of oestrogen (ER) and progesterone receptor (PgR), Ki-67, p53, bcl-2 proteins and the proteolytic enzymes cathepsin D (CD), urokinase-plasminogen activator (uPA) and its receptor (uPA-R) in primary carcinomas of the breast from indigenous Tanzanian female patients by immunohistochemistry. DESIGN: Prospective cross-sectional study. SETTING: Muhimbili Medical Centre, Dar es Salaam, Tanzania. SUBJECTS: Sixty patients admitted between 1995 and 1997. RESULTS: Markers were found to be expressed as follows: ER (33.3%), PgR (18.3%), p53 (30%), bcl-2 (43.5%) and the median proliferation rate of Ki-67 was 15%. Proportion of tumours positive for ER, PgR and bcl-2 initially decreased to 12 months disease duration, after which it increased. The observed proliferation rate approaches that reported in developed countries. p53 expression did not influence the proliferation rate nor did bcl-2 expression. ER, PgR and bcl-2 were strongly co-expressed. CD was predominantly expressed in stromal macrophages than in cancer cells. CONCLUSION: The low expression of ER and PgR and their strong co-expression with bcl-2 might negatively influence response to hormonal therapy. The influence of bcl-2 on tumour response to anti-cancer therapy in patients with long disease duration requires urgent clarification. Determination of CD in stromal macrophages rather than in cancer cells may have greater prognostic significance in patients of this region.
机译:目的:确定雌激素(ER)和孕激素受体(PgR),Ki-67,p53,bcl-2蛋白和蛋白水解酶组织蛋白酶D(CD),尿激酶纤溶酶原激活剂(uPA)及其受体(uPA)的表达-R)在坦桑尼亚原住民女性患者的乳腺原发癌中通过免疫组织化学检测。设计:前瞻性横断面研究。地点:坦桑尼亚达累斯萨拉姆Muhimbili医疗中心。对象:1995年至1997年期间收治的60例患者。结果:发现标记物的表达如下:ER(33.3%),PgR(18.3%),p53(30%),bcl-2(43.5%)和中位增殖Ki-67的发生率为15%。 ER,PgR和bcl-2阳性的肿瘤比例最初下降到疾病持续时间的12个月,此后又上升。观察到的扩散率方法已在发达国家报告。 p53表达不影响增殖速率,也不影响bcl-2表达。 ER,PgR和bcl-2强烈共表达。 CD主要在基质巨噬细胞中表达,而不是在癌细胞中表达。结论:ER和PgR的低表达以及它们与bcl-2的强共表达可能会对激素治疗产生负面影响。疾病持续时间长的患者中bcl-2对肿瘤对抗癌治疗反应的影响需要紧急阐明。在该区域的患者中,测定基质巨噬细胞而不是癌细胞中的CD可能具有更大的预后意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号